Real-world lecanemab in Chinese patients: low ARIA, financial-driven discontinuation
This large single-arm Chinese cohort provides pharmacists real-world safety, monitoring, and access data for lecanemab that extend beyond the Clarity Alzheimer's Disease (Clarity AD) trial population.
📅 Journal publication: Aug 2026·Last updated: Aug 6, 2026
Lecanemab shows safety but no cognitive boost in real-world AD study.
Lecanemab's safety and effectiveness in Alzheimer's disease (AD) need assessment in diverse populations. In 1,042 patients, amyloid-related imaging abnormalities occurred in 7.87% and infusion-related reactions in 16.12%. No change in Clinical Dementia Rating Scale-Sum of Boxes was seen at 12 months. The study shows lecanemab has a favorable safety profile but no notable cognitive improvement, highlighting the need for more research with control groups. Lecanemab demonstrates safety but no cognitive improvement in this 12-month study.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Wu H, Chen Q, Fang M, Tang H, Liu H, Liu J, Zhang J, Chi L, Liu S, Xin J, Leng L, Wang P, Chi S, Li Y, Chen J, Zhang L, Zhang J, Ma Q, Wang X, Meng X, Nao J, Li X, Lv Y, Jia Y, Zhao Q, Liu C, Gan J, Zhu J, Song Y, Li H, Fei M, Guo X, Liu J, Peng G, Chen X, Ji Y
Citation:Wu H, Chen Q, Fang M, et al. Lecanemab use in Chinese patients with Alzheimer's disease: a 12-month multicenter real-world study. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026;22(8):e71702. doi:10.1002/alz.71702